Literature DB >> 22497712

Nuclear carrier and RNA-binding proteins in frontotemporal lobar degeneration associated with fused in sarcoma (FUS) pathological changes.

Y S Davidson1, A C Robinson1, Q Hu1, M Mishra1, A Baborie1, E Jaros1, R H Perry1, N J Cairns1, A Richardson1, A Gerhard1, D Neary1, J S Snowden1, E H Bigio1, D M A Mann1.   

Abstract

AIMS: We aimed to investigate the role of the nuclear carrier and binding proteins, transportin 1 (TRN1) and transportin 2 (TRN2), TATA-binding protein-associated factor 15 (TAF15) and Ewing's sarcoma protein (EWS) in inclusion body formation in cases of frontotemporal lobar degeneration (FTLD) associated with fused in sarcoma protein (FTLD-FUS).
METHODS: Eight cases of FTLD-FUS (five cases of atypical FTLD-U, two of neuronal intermediate filament inclusion body disease and one of basophilic inclusion body disease) were immunostained for FUS, TRN1, TRN2, TAF15 and EWS. Ten cases of FTLD associated with TDP-43 inclusions served as reference cases.
RESULTS: The inclusion bodies in FTLD-FUS contained TRN1 and TAF15 and, to a lesser extent, EWS, but not TRN2. The patterns of immunostaining for TRN1 and TAF15 were very similar to that of FUS. None of these proteins was associated with tau or TDP-43 aggregations in FTLD.
CONCLUSIONS: Data suggest that FUS, TRN1 and TAF15 may participate in a functional pathway in an interdependent way, and imply that the function of TDP-43 may not necessarily be in parallel with, or complementary to, that of FUS, despite each protein sharing many similar structural elements.
© 2012 The Authors. Neuropathology and Applied Neurobiology © 2012 British Neuropathological Society.

Entities:  

Keywords:  Ewing's sarcoma protein; TATA-binding protein-associated factor 15; TDP-43; frontotemporal lobar degeneration; fused in sarcoma; transportins

Mesh:

Substances:

Year:  2013        PMID: 22497712      PMCID: PMC3479345          DOI: 10.1111/j.1365-2990.2012.01274.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  33 in total

1.  Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies.

Authors:  Deepak M Sampathu; Manuela Neumann; Linda K Kwong; Thomas T Chou; Matthew Micsenyi; Adam Truax; Jennifer Bruce; Murray Grossman; John Q Trojanowski; Virginia M-Y Lee
Journal:  Am J Pathol       Date:  2006-10       Impact factor: 4.307

2.  Heterodimerization with Jun family members regulates c-Fos nucleocytoplasmic traffic.

Authors:  Cécile E Malnou; Tamara Salem; Frédérique Brockly; Harald Wodrich; Marc Piechaczyk; Isabelle Jariel-Encontre
Journal:  J Biol Chem       Date:  2007-08-06       Impact factor: 5.157

Review 3.  Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria.

Authors:  D Neary; J S Snowden; L Gustafson; U Passant; D Stuss; S Black; M Freedman; A Kertesz; P H Robert; M Albert; K Boone; B L Miller; J Cummings; D F Benson
Journal:  Neurology       Date:  1998-12       Impact factor: 9.910

4.  Genetic contribution of FUS to frontotemporal lobar degeneration.

Authors:  T Van Langenhove; J van der Zee; K Sleegers; S Engelborghs; R Vandenberghe; I Gijselinck; M Van den Broeck; M Mattheijssens; K Peeters; P P De Deyn; M Cruts; C Van Broeckhoven
Journal:  Neurology       Date:  2010-02-02       Impact factor: 9.910

5.  FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration.

Authors:  Hazel Urwin; Keith A Josephs; Jonathan D Rohrer; Ian R Mackenzie; Manuela Neumann; Astrid Authier; Harro Seelaar; John C Van Swieten; Jeremy M Brown; Peter Johannsen; Jorgen E Nielsen; Ida E Holm; Dennis W Dickson; Rosa Rademakers; Neill R Graff-Radford; Joseph E Parisi; Ronald C Petersen; Kimmo J Hatanpaa; Charles L White; Myron F Weiner; Felix Geser; Vivianna M Van Deerlin; John Q Trojanowski; Bruce L Miller; William W Seeley; Julie van der Zee; Samir Kumar-Singh; Sebastiaan Engelborghs; Peter P De Deyn; Christine Van Broeckhoven; Eileen H Bigio; Han-Xiang Deng; Glenda M Halliday; Jillian J Kril; David G Munoz; David M Mann; Stuart M Pickering-Brown; Valerie Doodeman; Gary Adamson; Shabnam Ghazi-Noori; Elizabeth M C Fisher; Janice L Holton; Tamas Revesz; Martin N Rossor; John Collinge; Simon Mead; Adrian M Isaacs
Journal:  Acta Neuropathol       Date:  2010-05-20       Impact factor: 17.088

6.  Dissection of the molecular mechanisms that control the nuclear accumulation of transport factors importin-alpha and CAS in stressed cells.

Authors:  M Kodiha; P Bański; D Ho-Wo-Cheong; U Stochaj
Journal:  Cell Mol Life Sci       Date:  2008-06       Impact factor: 9.261

7.  PRMT1 mediated methylation of TAF15 is required for its positive gene regulatory function.

Authors:  Laure Jobert; Manuela Argentini; László Tora
Journal:  Exp Cell Res       Date:  2008-12-24       Impact factor: 3.905

8.  Frontal lobe dementia and motor neuron disease.

Authors:  D Neary; J S Snowden; D M Mann; B Northen; P J Goulding; N Macdermott
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-01       Impact factor: 10.154

9.  Identification of proteins interacting with protein arginine methyltransferase 8: the Ewing sarcoma (EWS) protein binds independent of its methylation state.

Authors:  Steffen Pahlich; Rouzanna P Zakaryan; Heinz Gehring
Journal:  Proteins       Date:  2008-09

10.  Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6.

Authors:  Caroline Vance; Boris Rogelj; Tibor Hortobágyi; Kurt J De Vos; Agnes Lumi Nishimura; Jemeen Sreedharan; Xun Hu; Bradley Smith; Deborah Ruddy; Paul Wright; Jeban Ganesalingam; Kelly L Williams; Vineeta Tripathi; Safa Al-Saraj; Ammar Al-Chalabi; P Nigel Leigh; Ian P Blair; Garth Nicholson; Jackie de Belleroche; Jean-Marc Gallo; Christopher C Miller; Christopher E Shaw
Journal:  Science       Date:  2009-02-27       Impact factor: 47.728

View more
  8 in total

Review 1.  Mechanisms of disease in frontotemporal lobar degeneration: gain of function versus loss of function effects.

Authors:  Glenda Halliday; Eileen H Bigio; Nigel J Cairns; Manuela Neumann; Ian R A Mackenzie; David M A Mann
Journal:  Acta Neuropathol       Date:  2012-08-10       Impact factor: 17.088

Review 2.  Fused in Sarcoma Neuropathology in Neurodegenerative Disease.

Authors:  Ian R A Mackenzie; Manuela Neumann
Journal:  Cold Spring Harb Perspect Med       Date:  2017-12-01       Impact factor: 6.915

3.  FUS is phosphorylated by DNA-PK and accumulates in the cytoplasm after DNA damage.

Authors:  Qiudong Deng; Christopher J Holler; Georgia Taylor; Kathryn F Hudson; William Watkins; Marla Gearing; Daisuke Ito; Melissa E Murray; Dennis W Dickson; Nicholas T Seyfried; Thomas Kukar
Journal:  J Neurosci       Date:  2014-06-04       Impact factor: 6.167

4.  The RNA-binding protein FUS is chaperoned and imported into the nucleus by a network of import receptors.

Authors:  Imke Baade; Saskia Hutten; Erin L Sternburg; Marius Pörschke; Mario Hofweber; Dorothee Dormann; Ralph H Kehlenbach
Journal:  J Biol Chem       Date:  2021-04-12       Impact factor: 5.157

Review 5.  Role of FET proteins in neurodegenerative disorders.

Authors:  Francesca Svetoni; Paola Frisone; Maria Paola Paronetto
Journal:  RNA Biol       Date:  2016-07-14       Impact factor: 4.652

6.  Arginine methylation next to the PY-NLS modulates Transportin binding and nuclear import of FUS.

Authors:  Dorothee Dormann; Tobias Madl; Chiara F Valori; Eva Bentmann; Sabina Tahirovic; Claudia Abou-Ajram; Elisabeth Kremmer; Olaf Ansorge; Ian R A Mackenzie; Manuela Neumann; Christian Haass
Journal:  EMBO J       Date:  2012-09-11       Impact factor: 11.598

7.  Heterogeneous ribonuclear protein A3 (hnRNP A3) is present in dipeptide repeat protein containing inclusions in Frontotemporal Lobar Degeneration and Motor Neurone disease associated with expansions in C9orf72 gene.

Authors:  Yvonne S Davidson; Louis Flood; Andrew C Robinson; Yoshihiro Nihei; Kohji Mori; Sara Rollinson; Anna Richardson; Bridget C Benson; Matthew Jones; Julie S Snowden; Stuart Pickering-Brown; Christian Haass; Tammaryn Lashley; David M A Mann
Journal:  Acta Neuropathol Commun       Date:  2017-04-21       Impact factor: 7.801

8.  Xrp1 genetically interacts with the ALS-associated FUS orthologue caz and mediates its toxicity.

Authors:  Moushami Mallik; Marica Catinozzi; Clemens B Hug; Li Zhang; Marina Wagner; Julia Bussmann; Jonas Bittern; Sina Mersmann; Christian Klämbt; Hannes C A Drexler; Martijn A Huynen; Juan M Vaquerizas; Erik Storkebaum
Journal:  J Cell Biol       Date:  2018-09-12       Impact factor: 10.539

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.